CRDF Q4 2017 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$133M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$185,000+172.1% YoY

Gross Profit

-$198,000-107.0% margin

Operating Income

-$4M-2045.4% margin

Net Income

-$3M-1389.2% margin

EPS (Diluted)

$-4.61

QoQ Revenue Growth

+50.0%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$895,221

Balance Sheet

Total Assets

$12M

Total Liabilities

$6M

Stockholders' Equity

$7M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$185,000	$68,000	+172.1%
Gross Profit	-$198,000	-$519,000	+61.8%
Operating Income	-$4M	-$10M	+61.3%
Net Income	-$3M	-$9M	+69.9%